New possibilities for diagnosis and treatment of osteoporosis

International Journal of Fertility and Women's Medicine

Volumn 46, Issue 4, 2001, Pages 215-221

  Miller, Paul D ^a  

^a NONE   (United States)

Author keywords

Bisphosphonates; Bone mineral density; Fracture risk; HRT; Measurement; Menopause; Prevention; SERM

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

AGE; ARTICLE; BONE DENSITY; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; EXERCISE; FEMALE; FRACTURE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR;

AGED; BONE DENSITY; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0035412481     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pouilles JM, Ribot C, Tremollieres F, et al: Risk factors for vertebral osteoporosis: Results of a study of 2279 women referred to a menopause clinic. Rev Rheum Mal Osteo-Arth 58:169-177, 1991.
2. The WHO Study Group: Assessment of fracture risk and its applications to screening for postmenopausal osteoporosis. Geneva, World Health Organization, 1994.
3. Rubin SM, Cummings SR: Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med 116:990-995, 1992.
4. Miller PD, Bonnick SL, Johnston CC, Jr, et al: The challenges of peripheral bone density testing. Which patients need additional central density skeletal measurements? J Clin Densitometry 1:211-217, 1998.
5. Hui SL, Slemenda CW, Johnston CC, Jr: Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804-1809, 1988.
6. Cummings SR, Black DM, Nevitt MC, et al: Bone density at various sites for prediction of hip fracture. Lancet 341:72-75, 1993.
7. Ross PD, Davis JW, Epstein RS, et al: Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919-923, 1991.
8. Faulkner KG, von Stetten E, Miller P: Discordance in patient classification using T-scores. J Clin Densitometry 2:343-350, 1999.
9. Steiger P for the International Committee for Standards in Bone Measurement: Letter to the editor: Standardization of spine BMD measurements. J Bone Miner Res 10:1602-1603, 1995.
10. Hanson J for the International Committee for Standards in Bone Measurement: Letter to the editor: Standardization of femur BMD. J Bone Miner Res 12:1316-1317, 1997.
11. Miller PD, Baran DT, Bilezikian JP, et al: Practical clinical application of biochemical markers of bone turnover. J Clin Densitometry 2:323-342, 1999.
12. Wasnich RD, Miller PD: Antifracture efficacy of antiresorptive agents is related to changes in bone density. J Clin Endocrinol Metabol 85:1-6, 2000.
13. Huang C, Ross PD, Wasnich RD: Short-term and long-term fracture prediction by bone mass measurements: A prospective study. J Bone Miner Res 13:107-113, 1998.
14. Cummings SR, Black DM, Rubin SM: Lifetime risks of hip, Colles' or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149:2556-2448, 1989.
15. 16. Kanis JA: Determinants of skeletal mass and strength, in Kanis JA (ed): Textbook of Osteoporosis. Oxford, Blackwell Science, pp 106-147, 1996.
16. Cummings SR, Black DM, Vogt TM, et al: Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs. J Bone Miner Res 11:S102, 1996.
17. Cummings SR, Palermo L, Browner W, et al: Monitoring osteoporosis therapy with bone densitometry. JAMA 283:1318-1321, 2000.
18. Bonnick SL: Bone Densitometry in Clinical Practice: Application and Interpretation. Humana Press, Totowa, NJ, 1998.
19. Harris ST, Watts NB, Genant HK, et al: The effects of risedronate treatment on vertebral and non-vertebral fractures in women with postemenopausal osteoporosis: A double-blind, randomized, placebo-controlled trial. JAMA 282:1344-1352, 1999.
20. McClung MR, Gensens P, Miller PD, et al: Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340, 2001.
21. Reginster J-Y, Minne HW, Sorensen OH, et al: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 11:83-91, 2000.
22. Black DM, Cummings SR, Karpf DB, et al: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 358:1535-1541, 1996.
23. Lauritzen JB, Petersen MM, Lund B: Effect of external hip protectors on hip fractures. Lancet 341:11-13, 1993.
24. Tinetti ME, Baker DI, McAvay G, et al: A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 331:821-827, 1994.
25. Kamus P, Parkkari J, Niemi S, et al: Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 343:1506-1513, 2000.